Values as of: 2024-04-19
COMMON STOCK | Medical Distribution |
Last Closing
USD 4.59Change
0.00 (0.00)%Market Cap
USD 1.27BVolume
N/AAnalyst Target
N/AVerdict
Verdict
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| MCK | McKesson Corporation |
-0.83 (-0.16%) |
USD 70.80B |
| COR | Cencora Inc. |
-4.46 (-1.95%) |
USD 38.52B |
| CAH | Cardinal Health Inc |
+0.81 (+0.79%) |
USD 26.32B |
| OMI | Owens & Minor Inc |
+0.50 (+2.08%) |
USD 2.06B |
| NVG | Nuveen AMT Free Municipal Cred.. |
+0.07 (+0.60%) |
USD 3.29M |
N/A
| Market Performance vs. Industry/Classification (Medical Distribution) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 19.84% | 83% | B | 94% | A | ||
| Dividend Return | 23.50% | 100% | F | 100% | F | ||
| Total Return | 43.34% | 100% | F | 98% | N/A | ||
| Trailing 12 Months | |||||||
| Capital Gain | 14.75% | 33% | F | 71% | C- | ||
| Dividend Return | 22.50% | 100% | F | 100% | F | ||
| Total Return | 37.25% | 33% | F | 89% | A- | ||
| Trailing 5 Years | |||||||
| Capital Gain | 31.14% | 33% | F | 67% | D+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 31.14% | 33% | F | 58% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 12.71% | 33% | F | 77% | C+ | ||
| Dividend Return | 20.08% | 50% | F | 83% | B | ||
| Total Return | 7.37% | 100% | F | 90% | A- | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 48.13% | 33% | F | 20% | F | ||
| Risk Adjusted Return | 41.71% | 33% | F | 66% | D+ | ||
| Market Capitalization | 1.27B | 33% | F | 58% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
